Child with Atopic Dermatitis Photo by Eisfelder via Wikimedia Commons A new study shows that treatment with dupilumab significantly restores skin barrier function and reduces inflammation in children aged 6 to 11 years with moderate-to-severe atopic dermatitis (AD). Researchers found improvements not only in visible AD lesions but also in clinically unaffected skin, highlighting the systemic nature of the disease. The findings were published in Annals of Allergy, Asthma & Imm

In a recent study, researchers at National Jewish Health investigated the impact of dupilumab on the vascular barrier function in...

Researchers have identified an immune and lipid profile on the surface of the skin of infants that can predict the development of atopic...